PHILADELPHIA, PA — Dispatch Bio said it will present new preclinical data on its SEND T cell engineering platform at the ASGCT 2026 Annual Meeting, highlighting experimental results showing anti-tumor activity in solid tumor models.
The company said the findings involve SEND, short for Synthetic Efficacy eNableD, a synthetic cytokine receptor platform designed to activate multiple T cell signaling pathways simultaneously.
According to Dispatch Bio, the data showed SEND-armored CAR T cells achieved tumor clearance in animal models at low doses while maintaining what the company described as a favorable safety profile.
The presentation is scheduled for May 14 during a poster session at the ASGCT 2026 Annual Meeting.
Lex Johnson, co-founder and chief platform officer of Dispatch Bio, said the platform was designed to address limitations associated with single-cytokine signaling approaches in engineered T cell therapies.
“Engineering T cells with a single cytokine signal often forces a tradeoff between proliferation, persistence, and effector function,” Johnson said.
The company said single-cell RNA sequencing analysis showed simultaneous activation of effector and memory gene programs within the same engineered T cells, which it said may support durability while limiting exhaustion.
Barbra Sasu, chief scientific officer at Dispatch Bio, said the platform could potentially be applied across several engineered cell therapy approaches, including CAR T and TCR-based treatments.
The company also said the experimental therapy demonstrated anti-tumor activity both with and without lymphodepleting chemotherapy in preclinical testing.
Dispatch Bio is developing cancer therapies using what it describes as its Flare platform, focused on engineered T cell treatments targeting solid tumors.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.